Advertisement

New pharmacological approaches in the treatment of mild hypertension. The potential role of converting enzyme inhibitors and calcium blocking agents

  • F. Alhenc-Gelas
  • P. Corvol
  • J. Menard

Abstract

Control of blood pressure in hypertension has generally been achieved in the past by the use of diuretics and betablockers, either alone or in combination with vasodilators or drugs interacting with the sympathetic nervous system. These treatments obviously have highly beneficial effects since several controlled trials have shown that lowering of blood pressure reduces cardiovascular mortality and morbidity in treated hypertensive patients. (Australian Therapeutic Trial of Mild Hypertension 1980; Smith 1977; Veterans Administration Cooperative Study Group 1970). There are, however, some limitations in this approach to the treatment of hypertension. In approximately two thirds of unselected patients, satisfactory control of blood pressure is not obtained with the drug of first choice alone. Therefore it is often necessary to prescribe two or more drugs. The antihypertensive effect of diuretics can be limited by overstimulation of the renin-angiotensin system (Alhenc-Gelas et al. 1978; Laragh 1973) and that of vasodilators by sodium retention (Ibsen et al. 1978). Side-effects such as postural hypotension, disturbance of the microcirculation or erectile dysfunction are not uncommon (Smith 1977). Recently, two new classes of antihypertensive agent: converting enzyme inhibitors and calcium channel blockers, became available for the treatment of hypertension (Table 1). Although their mechanisms of action vary they are all able to decrease vascular resistance and lower blood pressure in patients with mild to severe hypertension.

Keywords

Hypertensive Patient Angiotensin Converting Enzyme Calcium Antagonist Lower Blood Pressure Plasma Renin Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aldigier JC, Plouin PF, Alexandre JM, Corvol P, Menard J (1981) Dose dependency of Captopril effects in severely hypertensive patients. J Cardiovasc Pharmacol 3:1229–1235.PubMedCrossRefGoogle Scholar
  2. 2.
    Aldigier JC, Plouin PF, Guyene TT, Thibonnier M, Corvol P, Menard J (1982) Comparison of the hormonal and renal effects of Captopril in severe essential and renovascular hypertension. Am J Cardiol 49:1447–1452.PubMedCrossRefGoogle Scholar
  3. 3.
    Alhenc-Gelas F, Plouin P-F, Ducrocq M-B, Corvol P, Menard J (1978) Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. Am J Med 64:1005–1012.PubMedCrossRefGoogle Scholar
  4. 4.
    Aoki K, Kondo Mochizaki A, Yoshida T, Kato S, Kato K, Takiwawa K (1978) Antihypertensive effect of Ca2 + antagonist in hypertensive patients in the absence and presence of beta adrenergic blockage. Am Heart J 96:218–226.PubMedCrossRefGoogle Scholar
  5. 5.
    Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN (1979) Interruption of the renin-angiotensin system in hypertensive patients by Captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1:274–280.PubMedGoogle Scholar
  6. 6.
    Australian Therapeutic Trial in mild hypertension. Report by the Management Committee (1980) Lancet i: 1261–1267.Google Scholar
  7. 7.
    Bertel O, Conen D, Radu EW, Muller J, Lang C, Dubach UC (1983) Nifedipine in hypertensive emergencies. Br Med J 286:19–21.CrossRefGoogle Scholar
  8. 8.
    Bühler FR, Hulthén UL, Kiowski W, Müller FB, Bolli P (1982) The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol 4: S350–S357.PubMedCrossRefGoogle Scholar
  9. 9.
    Case DB, Atlas SA, Laragh JH, Sullivan PA, Sealey JE (1980) Use of first-dose response or plasma renin activity to predict the long term effect of Captopril: identification of triphasic pattern of blood pressure response. J Cardiovasc Pharmacol 2:339–346.PubMedCrossRefGoogle Scholar
  10. 10.
    Clauser E, Genain C, Bouhnik, Corvol P, Menard J (1982) Variations de l’angiotensinogene et du des-angiotensine I-angiotensinogene chez l’homme et le rat au cours de l’inhibition de l’enzyme de conversion. Arch Mal Coeur n° Special; 157–161.Google Scholar
  11. 11.
    Cody RJ, Burton J, Evin G, Poulsen K, Herd JA, Haber E (1980) A substrate analog inhibitor of renin that is effective in vivo. Biochem Biophys Res Commun 97:230–235.PubMedCrossRefGoogle Scholar
  12. 12.
    Cushman DW, Cheung HS, Sabo EF, Ondetti MA (1977) Design of potent competitive inhibitors of angiotensin-converting enzyme. Biochemistry 16:5484–5491.PubMedCrossRefGoogle Scholar
  13. 13.
    Erdos EG (1976) Conversion of angiotensin I to angiotensin II. Am J Med 60:749–759.PubMedCrossRefGoogle Scholar
  14. 14.
    Fagard R, Amery A, Lijnen P, Reybrouck T (1979) Haemodynamic effects of Captopril in hypertensive patients comparison with saralasin. Clin Sci 57:131S–134S.PubMedGoogle Scholar
  15. 15.
    Ferguson RK, Brunner HR, Turini GA, Gavras H, McKinstry DN (1977) A specific orally active inhibitor of angiotensin converting enzyme in man. Lancet i: 775–778.CrossRefGoogle Scholar
  16. 16.
    Gardes J, Evin G, Castro B, Corvol P, Menard J (1980) Synthesis and renin inhibitory properties of a new soluble pepstatin derivative. J Cardiovasc Pharmacol 2:687–698.PubMedCrossRefGoogle Scholar
  17. 17.
    Heel RC, Brodgen RN, Speight TM, Avery GS (1980) Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20:409–452.PubMedCrossRefGoogle Scholar
  18. 18.
    Huang CM, Saloman J, Molteni A, Quintanilla A, De Greco F (1980) Antihypertensive effect of Captopril and propranolol. Clin Pharmacol Ther 27:258–259.Google Scholar
  19. 19.
    Ibsen H, Rasmussen K, Jensen HAE, Leth A (1978) Changes in plasma volume and extracellular fluid volume after addition of hydralazine to propranolol in patients with hypertension. Acta Med Scand 203:419–423.PubMedCrossRefGoogle Scholar
  20. 20.
    Jenkins AC, MacKinstry DN (1979) Review of clinical studies of hypertensive patients treated with Captopril. Med J Aust 2: (Suppl 2) xxxii–xxxvii.Google Scholar
  21. 21.
    Laragh JH (1973) Vasoconstriction volume analysis for understanding and treating hypertension. The use of renin and aldosterone profiles. Am J Med 55:261–274.PubMedCrossRefGoogle Scholar
  22. 22.
    Lederballe Petersen O, Christensen NJ, Rämsch KD (1980) Comparison of acute effects of nifedipine in normotensive and hypertensive man. J Cardiovasc Pharmacol 2:357–366.CrossRefGoogle Scholar
  23. 23.
    Levenson J, Simon A, Tremmar M, Safar M (1980) Action antihypertensive du Captopril: etude hemdynamique. Nouv Presse Med 9:617–619.PubMedGoogle Scholar
  24. 24.
    Lewis GRJ, Stewart DJ, Lewis BM, Bones PJ, Morley KD, Janus ED (1981) The antihypertensive effect of oral verapamil. Acute and long term administration and its effects on the high density lyoprotein values in plasma. In: Zanchetti and Kreber (eds) Calcium antagonism in cardiovascular therapy. Experience with verapamil. Excerpta Medica, Amsterdam-Oxford-Princetown 270–277.Google Scholar
  25. 25.
    MacGregor GA, Markander ND, Roulston JA, Jones JC, Morton JJ (1981) The renin angiotensin system: a normal mechanism for maintaining blood pressure in normotensive and hypertensive subjects. In: Angiotensin converting enzyme inhibitors Morowitz ZP (ed) Urban and Swarzenberg-Baltimore 329–349.Google Scholar
  26. 26.
    MacGregor GA, Markandu ND, Banks RA, Bayliss J, Rouston JE, Jones JC (1982a) Captopril in essential hypertension contrasting effects of adding hydrochlorothiazide or propranolol. Br Med J 284:693–698.CrossRefGoogle Scholar
  27. 27.
    MacGregor GA, Rotellar C, Markandu ND, Smith SS, Sagnella GA (1982b) Contrasting effects of nifedipine, Captopril and propranolol in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 4 (Suppl 3):S358–S362.PubMedCrossRefGoogle Scholar
  28. 28.
    Maeda K, Takasugi T, Tsukano Y, Tanaka Y, Shiota K (1981) Clinical study on the hypertensive effect of diltiaziem hydrochloride. Int J Clin Pharmacol Therap Toxic 19:47–55.Google Scholar
  29. 29.
    Mimran A, Brunner HR, Turini GA, Waeber B, Brunner D (1979) Effect of Captopril on renal vascular tone in patients with essential hypertension. Clin Sci 57:421S–432SPubMedGoogle Scholar
  30. 30.
    Muiesan G, Abigiti-Rosei E, Alicandri C, Bescki M, Castercano M, Corea L, Fariello R, Romanelli G, Pasini C, Platto L (1981) Influence of verapamil on catecholamines renin and aldosterone in essential hypertensive patients. In: Zanchetti and Krikler (eds) Calcium antagonism in cardiovascular therapy. Experience with verapamil. Excerpta Medica, Amsterdam-Oxford-Princeton 238–249.Google Scholar
  31. 31.
    Olivart MT, Bartorelli C, Polese A, Fiorentini O, Moruzzi P, Guazzi MD (1979) Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation 59:1056–1062.Google Scholar
  32. 32.
    Soto ME, Thibonnier M, Sire O, Menard J, Corvol P, Milliez P (1981) Antihypertensive and hormonal effects of single oral doses of Captopril and nifedipine in essential hypertension. Eur J Clin Pharmacol 20:157–161.PubMedCrossRefGoogle Scholar
  33. 33.
    Spivack C, Ocken S, Frishman WH (1983) Calcium antagonists: clinical use in the treatment of systemic hypertension. Drugs: 25:154–177.PubMedCrossRefGoogle Scholar
  34. 34.
    Triggle DJ, Swamy VC (1983) Calcium antagonists: some chemical-pharmacologic aspects. Circ Res 52 (Suppl 1): 17–28.Google Scholar
  35. 35.
    Patchett AA, Harris E, Tristram E, et al. (1981) A new class of angiotensin — converting enzyme inhibitors. Nature 288:280–283.CrossRefGoogle Scholar
  36. 36.
    Smith WM (1977) US Public Health Service Hospitals Cooperative Study Group. Treatment of mild hypertension. Results of ten year intervention trial. Circ Res 40 (Suppl i): 98–105.Google Scholar
  37. 37.
    Veterans Administration Cooperative Study Group on antihypertensive agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213 C: 1143–1152.Google Scholar
  38. 38.
    Weinberger MH (1980) Angiotensin converting enzyme (ACE 1) inhibition in treatment of resistant hypertension. Clin Pharmacol Ther 27:293.Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1984

Authors and Affiliations

  • F. Alhenc-Gelas
    • 1
  • P. Corvol
  • J. Menard
  1. 1.Hopital BroussaisParisFrance

Personalised recommendations